OLUMIANT Drug Patent Profile

Which patents cover Olumiant, and what generic alternatives are available?

Olumiant is a drug marketed by Eli Lilly And Co and MSN and is included in two NDAs. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and five patent family members in forty-four countries.

The generic ingredient in OLUMIANT is baricitinib. One supplier is listed for this compound. Additional details are available on the baricitinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Olumiant

Olumiant was eligible for patent challenges on May 31, 2022.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for OLUMIANT

International Patents:	105
US Patents:	6
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	100
Clinical Trials:	16
Patent Applications:	3,173
Drug Prices:	Drug price information for OLUMIANT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OLUMIANT
What excipients (inactive ingredients) are in OLUMIANT?	OLUMIANT excipients list
DailyMed Link:	OLUMIANT at DailyMed

See drug prices for OLUMIANT

Recent Clinical Trials for OLUMIANT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of North Carolina, Chapel Hill	Phase 2
Vanderbilt University	Phase 2
Emory University	Phase 2

See all OLUMIANT clinical trials

Pharmacology for OLUMIANT

Drug Class	Janus Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Paragraph IV (Patent) Challenges for OLUMIANT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OLUMIANT	Tablets	baricitinib	4 mg	207924	1	2023-10-03
OLUMIANT	Tablets	baricitinib	1 mg and 2 mg	207924	2	2022-05-31

US Patents and Regulatory Information for OLUMIANT

OLUMIANT is protected by six US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-002	Oct 8, 2019	AB	RX	Yes	No	9,737,469
Msn	OLUMIANT	baricitinib	TABLET;ORAL	217585-001	Aug 8, 2025	AB	RX	No	No
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018	AB	RX	Yes	No	9,737,469
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-002	Oct 8, 2019	AB	RX	Yes	No	8,420,629
Eli Lilly And Co	OLUMIANT	baricitinib	TABLET;ORAL	207924-001	May 31, 2018	AB	RX	Yes	No	8,158,616		Y	Y

EU/EMA Drug Approvals for OLUMIANT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Olumiant	baricitinib	EMEA/H/C/004085Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate.	Authorised	no	no	no	2017-02-13

International Patents for OLUMIANT

When does loss-of-exclusivity occur for OLUMIANT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Mexico

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OLUMIANT around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20140148459
European Patent Office	2785184	COMPOSITIONS CONTENANT DES INHIBITEURS DE JAK ET DES MÉDICAMENTS HAART DESTINÉES À LA PRÉVENTION OU AU TRAITEMENT DU VIH (COMPOSITIONS COMPRISING JAK INHIBITORS AND HAART DRUGS FOR USE IN THE PREVENTION OR TREATMENT OF HIV)
Serbia	55263	DERIVATI AZETIDINA I CIKLOBUTANA KAO JAK INHIBITORI (AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS)
Slovenia	2288610
Taiwan	200942545	Azetidine and cyclobutane derivatives as JAK inhibitors

Supplementary Protection Certificates for OLUMIANT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2288610	122017000045	Germany		PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: EU/1/16/1170 20170213
2288610	33/2017	Austria		PRODUCT NAME: BARICITINIB UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; REGISTRATION NO/DATE: EU/1/16/1170 (MITTEILUNG) 20170215
2288610	C02288610/01	Switzerland		PRODUCT NAME: BARICITINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66215 19.06.2017
2288610	655	Finland
2288610	2017/032	Ireland		PRODUCT NAME: BARACITINIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTRATION NO/DATE: EU/1/16/1170 20170213

Market Dynamics and Financial Trajectory for Olumiant (Baricitinib)

Last updated: February 20, 2026

What are the current market drivers for Olumiant?

Olumiant (baricitinib) is a Janus kinase (JAK) inhibitor approved primarily for rheumatoid arthritis (RA), with additional approvals for COVID-19 and atopic dermatitis. Its market growth is influenced by several factors:

• Indications Expansion: Recently approved for COVID-19, the drug benefits from emergency use authorizations (EUAs) and full approvals in multiple jurisdictions.

• Rheumatoid Arthritis Market: RA remains the primary market; the drug is positioned as an oral alternative to injectable biologics.

• Market Penetration and Prescribing Trends: Increased confidence among physicians due to positive clinical trial results, especially in patients refractory to other DMARDs.

• Competitive Landscape: Competes with other JAK inhibitors (e.g., tofacitinib, upadacitinib), as well as biologic agents targeting TNF-alpha, IL-6, and B-cell pathways.

• Pricing Strategies: Pricing is aligned with other oral JAK inhibitors; patents and exclusivity shape revenue potential in key markets.

• Regulatory Approvals: Recent approvals for COVID-19 expand indications, but maintain regulatory scrutiny and post-market safety requirements.

How does the market size for Olumiant evolve?

The global rheumatoid arthritis market is projected to reach USD 32 billion by 2025, growing at a CAGR around 4.5% [1]. JAK inhibitors like Olumiant claim a significant portion due to oral administration:

Year	Estimated RA Market Size (USD billion)	Olumiant's Market Share
2021	24.2	4-6%
2023	27.8	6-8%
2025	32	8-10%

In COVID-19, Olumiant gained emergency authorization in the U.S. and Europe, adding a new revenue stream, albeit with uncertainties around pandemic resolution and treatment protocols.

What are the key financial metrics and projections?

Revenue Estimates

• 2022: Estimated USD 600-700 million; primarily driven by RA sales in North America and Europe.
• 2023: Forecasted to surpass USD 1 billion, as COVID-19 treatment uptake stabilizes or declines.
• 2025: Potential revenues of USD 1.5-2 billion if global RA market and COVID-19 indications sustain growth.

Profitability and Margins

• Gross Margin: Estimated at 70%, reflecting high-margin specialty drugs.
• R&D Expenses: Approximately 25-30% of revenue targeted toward pipeline expansion and safety studies.
• Pricing Pressure: Increased competition could reduce margins; patent expirations forecasted post-2028.

Licensing and Collaborations

• Partnerships: Eli Lilly markets Olumiant under licensing agreements, with royalties accounting for 15-20% of revenues.
• Patent Lifecycle: Patents expire in 2030-2035, opening generic competition thereafter.

How do competitive factors influence the financial trajectory?

• Generic Entry: Expected post-2030; will impact sales volume and pricing.
• Pipeline Development: Additional indications in psoriatic arthritis, alopecia areata, and other autoimmune diseases could extend revenue streams.
• Regulatory Risks: Safety concerns related to infections could lead to restrictions, affecting sales.

What are future market scenarios?

Scenario	Assumptions	Impact on Olumiant Revenue
Optimistic	Rapid RA market growth, successful expansion into additional indications	USD 2.5-3 billion (2025)
Moderate	Slow RA growth, limited indication expansion	USD 1-1.5 billion (2025)
Pessimistic	Regulatory constraints, competitive erosion	USD 500-800 million (2025)

Conclusion

Olumiant's market is driven by its repositioning as both an RA and COVID-19 treatment. Revenue growth hinges on broader indication approvals, competitive dynamics, and regulatory developments. The drug’s financial trajectory is projected to expand significantly through the mid-2020s, with revenue potentially surpassing USD 2 billion if current trends continue.

---

Key Takeaways

• Olumiant's primary revenue stems from RA treatment, with recent COVID-19 approval adding variability.
• The global RA market is expanding, supporting Olumiant’s ascent, but faces competition from biologics and other JAK inhibitors.
• Revenue estimates for 2023 forecast above USD 1 billion, with potential to reach USD 2 billion or more, contingent on market conditions.
• Patent expirations post-2028 and competition from generics will influence long-term profitability.
• Pipeline expansion into other autoimmune indications offers growth opportunities but remains uncertain.

---

FAQs

1. When will Olumiant face generic competition?
Post-2030, when patents expire or are challenged in key markets, generic competitors are likely to enter.

2. What are the main risks for Olumiant's financial growth?
Regulatory restrictions, safety concerns, patent expirations, and increased competition pose significant risks.

3. How does Olumiant compare with other JAK inhibitors?
It has similar efficacy but differs in pricing, safety profile, and approved indications. Tofacitinib and upadacitinib hold larger market shares but face similar competitive pressures.

4. Can new indications extend Olumiant’s revenue beyond RA and COVID-19?
Yes; development in alopecia areata, psoriatic arthritis, and other autoimmune diseases could generate additional revenue streams.

5. What are regulatory developments to watch?
Post-market safety evaluations and approval status updates for new indications are critical. The FDA’s safety communications and EMA decisions influence market access.

---

References

[1] Grand View Research. (2021). Rheumatoid Arthritis Treatment Market Size, Share & Trends Analysis Report.